An allogeneic, off-the-shelf CD70-directed CAR T-cell therapy (UCAR-T). Gene-engineered T cells express a chimeric antigen receptor targeting CD70 to activate T-cell signaling (CD3ζ and costimulatory domains), leading to cytokine release and cytolytic elimination of CD70-positive tumor cells and modulation of the CD70–CD27 axis.
Allogeneic (off-the-shelf) T cells are gene-engineered to express a CD70-directed chimeric antigen receptor. Upon binding CD70 on tumor cells, CAR signaling (CD3zeta with costimulatory domains) activates T-cell effector functions, leading to cytokine release and targeted cytolytic killing of CD70-positive cells and modulation of the CD70–CD27 axis, independent of the native T-cell receptor.
CD70-directed CAR T cells bind CD70 on target cells, triggering CAR signaling and T‑cell effector functions that kill CD70-positive cells via perforin/granzyme-mediated cytolysis (and death receptor pathways).
Chimeric IgG1 monoclonal antibody targeting EGFR to block ligand-mediated signaling and promote antibody-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody that binds the extracellular domain of EGFR, blocking ligand binding and receptor dimerization to inhibit downstream MAPK signaling and tumor cell proliferation; its Fc region also engages immune effector cells to promote antibody-dependent cellular cytotoxicity (ADCC).
Cetuximab binds EGFR on target cells and its IgG1 Fc engages FcγR-bearing immune cells (e.g., NK cells) to induce ADCC (and potentially complement-mediated lysis), killing EGFR+ cells; signaling blockade is antiproliferative.
Chimeric IgG1 monoclonal antibody targeting EGFR (ERBB1); blocks ligand binding and receptor dimerization, inhibits downstream MAPK and PI3K/AKT signaling, and induces Fcγ-mediated ADCC.
Chimeric IgG1 monoclonal antibody against EGFR (ERBB1) that blocks ligand binding and receptor dimerization, inhibiting downstream MAPK and PI3K/AKT signaling to suppress tumor cell proliferation and survival; Fc region engages Fcγ receptors to induce NK cell–mediated ADCC.
Fc region engages Fcγ receptors on NK cells to mediate ADCC against EGFR-expressing cells (and may also trigger CDC).
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
Imatinib binds the ATP site of ABL1/BCR‑ABL, blocking autophosphorylation and downstream MAPK/PI3K‑AKT survival signaling, leading to cell‑cycle arrest and apoptosis in ABL‑dependent (e.g., BCR‑ABL+) cells.
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
Imatinib directly inhibits PDGFRA kinase activity, blocking autophosphorylation and downstream MAPK/PI3K-AKT signaling, leading to growth arrest and apoptosis in PDGFRA-dependent cells.